心脏手术后循环分泌神经肽浓度:来自芬兰急性肾损伤心脏研究的数据
该研究为多中心研究中的单中心前瞻性观察性子研究,纳入619例接受心脏手术的患者,测量术前和术后分泌神经肽浓度,并针对欧洲心脏手术风险评估系统II、N末端B型利钠肽原和心肌肌钙蛋白T进行多因素校正。中位随访961天期间59例(9.5%)死亡。非幸存者术前和术后分泌神经肽浓度均高于幸存者,幸存者术后浓度较术前下降,而非幸存者无显著下降。术后分泌神经肽浓度与死亡时间独立相关(HR 2.96,95%CI 1.46-5.99),加入欧洲心脏手术风险评估系统II后改善风险分层(综合判别指数0.023)。
要点
- 心脏手术后分泌神经肽浓度升高与死亡风险独立相关:多因素Cox回归HR 2.96(95%CI 1.46-5.99,p=0.003)。
- 非幸存者术后分泌神经肽浓度173 pmol/L(129-217)高于幸存者143 pmol/L(111-173),p<0.001。
- 幸存者术后分泌神经肽浓度较术前下降,非幸存者无显著下降。
- 术后分泌神经肽加入欧洲心脏手术风险评估系统II改善风险分层,综合判别指数0.023(95%CI 0.0043-0.041,p=0.016)。
- 分泌神经肽与现有风险指标仅弱相关,提示其提供独立于传统标志物的预后信息。
适用人群与场景
- 接受心脏手术的患者,包括孤立冠状动脉旁路移植术、单一非冠状动脉旁路移植手术、两种手术或三种及以上手术;非冠状动脉旁路移植手术包括瓣膜手术、胸主动脉手术和其他心脏手术。
研究设计与关键结果
- 研究类型:多中心研究中的单中心前瞻性观察性子研究;样本量619例;人群为接受心脏手术的患者。
- 随访961天期间59例(9.5%)死亡。
- 非幸存者术前分泌神经肽浓度168 pmol/L(四分位距147-206)高于幸存者160 pmol/L(131-193),p=0.039;术后非幸存者173 pmol/L(129-217)高于幸存者143 pmol/L(111-173),p<0.001。
- 幸存者术后分泌神经肽浓度较术前下降,非幸存者无显著下降。
- 术后分泌神经肽浓度最高组预后较差(log-rank检验p<0.001);多因素Cox回归分析中术后分泌神经肽浓度与死亡时间相关,HR(ln分泌神经肽)2.96(95%CI 1.46-5.99,p=0.003)。
- 将术后分泌神经肽浓度加入欧洲心脏手术风险评估系统II改善风险分层,综合判别指数0.023(95%CI 0.0043-0.041,p=0.016)。
证据类型、等级与局限
- 证据类型:前瞻性观察性子研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 术后分泌神经肽浓度可为心脏手术患者提供增量预后信息,辅助识别高危患者。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: Secretoneurin is associated with cardiomyocyte Ca handling and improves risk prediction in patients with acute myocardial dysfunction. Whether secretoneurin improves risk assessment on top of established cardiac biomarkers and European System for Cardiac Operative Risk Evaluation II in patients undergoing cardiac surgery is not known.
DESIGN: Prospective, observational, single-center sub-study of a multicenter study.
SETTING: Prospective observational study of survival in patients undergoing cardiac surgery.
PATIENTS: A total of 619 patients undergoing cardiac surgery.
INTERVENTIONS: Patients underwent either isolated coronary artery bypass graft surgery, single noncoronary artery bypass graft surgery, two procedures, or three or more procedures. Procedures other than coronary artery bypass graft were valve surgery, surgery on thoracic aorta, and other cardiac surgery.
MEASUREMENTS AND MAIN RESULTS: We measured preoperative and postoperative secretoneurin concentrations and adjusted for European System for Cardiac Operative Risk Evaluation II, N-terminal pro-B-type natriuretic peptide, and cardiac troponin T concentrations in multivariate analyses. During 961 days of follow-up, 59 patients died (9.5%). Secretoneurin concentrations were higher among nonsurvivors compared with survivors, both before (168 pmol/L [quartile 1-3, 147-206 pmol/L] vs 160 pmol/L [131-193 pmol/L]; p = 0.039) and after cardiac surgery (173 pmol/L [129-217 pmol/L] vs 143 pmol/L [111-173 pmol/L]; p < 0.001). Secretoneurin concentrations decreased from preoperative to postoperative measurements in survivors, whereas we observed no significant decrease in secretoneurin concentrations among nonsurvivors. Secretoneurin concentrations were weakly correlated with established risk indices. Patients with the highest postoperative secretoneurin concentrations had worse outcome compared with patients with lower secretoneurin concentrations (p < 0.001 by the log-rank test) and postoperative secretoneurin concentrations were associated with time to death in multivariate Cox regression analysis: hazard ratio lnsecretoneurin 2.96 (95% CI, 1.46-5.99; p = 0.003). Adding postoperative secretoneurin concentrations to European System for Cardiac Operative Risk Evaluation II improved patient risk stratification, as assessed by the integrated discrimination index: 0.023 (95% CI, 0.0043-0.041; p = 0.016).
CONCLUSIONS: Circulating postoperative secretoneurin concentrations provide incremental prognostic information to established risk indices in patients undergoing cardiac surgery.
参考来源
- Brynildsen J, Petäjä L, Myhre PL, et al. Circulating Secretoneurin Concentrations After Cardiac Surgery: Data From the FINNish Acute Kidney Injury Heart Study. Crit Care Med. 2019. PMID: 30730440. doi:10.1097/CCM.0000000000003670
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。